Field Medical Advisor - Belgium
CSLSalary not specified
- Full Time
- Junior (1 to 2 years)
About CSL
CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves a wide range of clients, including healthcare providers and governments, across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its comprehensive portfolio and commitment to addressing rare diseases, alongside a strong emphasis on diversity and inclusion within its workforce. The company's goal is to save lives and protect health through its innovative therapies and vaccines.
Parkville, AustraliaHeadquarters
1916Year Founded
$2,628.7MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees
Risks
Emerging synthetic biomaterials may reduce demand for traditional plasma therapies.
Jumar Bioincubator could increase local competition in the biotech sector.
CSL may need to adapt to the rising effectiveness of cell-based influenza vaccines.
Differentiation
CSL offers the broadest range of plasma-derived and recombinant therapies globally.
CSL's self-amplifying mRNA COVID-19 vaccine provides longer immunity at lower doses.
CSL's MF59® adjuvant enhances immune response, crucial for pandemic preparedness.
Upsides
CSL's garadacimab could be the first monthly treatment for hereditary angioedema.
CSL's cell-based influenza vaccine shows higher effectiveness over egg-based vaccines.
CSL's gene therapy HEMGENIX® offers a one-time treatment for haemophilia B.
Funding
Total raised$2.63 B
Latest valuation$18.80 B
StageACQUISITION
ACQUISITION
11/30/2013$18.8 K
$18.80 B